APC-100 is an orally available anti-androgenic/anti-inflammatory, signal transduction inhibitor drug.
The recently issued patent strengthens company’s patent portfolio for the use of APC-100 in the treatment of early and late stage prostate cancer.
The patent covers method of inhibiting the growth of prostate cancer cells; delaying the progression of prostate cancer; and, preventing the recurrence of prostate cancer.
Adamis plans to begin FDA approved Phase 1/2a clinical studies of APC-100 in men with castrate resistant prostate cancer (CRPR).